Recent Updates
Recently added Catalysts

COVID-19 Vaccine

Phase 2

COVID-19 Infection | Monoclonal antibody | Oncology |GeoVax Labs, Inc.|Last Updated: Feb 10, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment63
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04977024SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerPHASE2 ACTIVE NOT_RECRUITING 63 — — Sep 1, 2021Dec 1, 2027Feb 10, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
COVID-19 VaccineBIOLOGICALReceive SOC mRNA SARS-CoV-2 vaccine IM
Diagnostic Laboratory Biomarker AnalysisOTHERCorrelative studies
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1BIOLOGICALGiven IM
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT04977024studyFirstPostDate: changed